JP2009523777A5 - - Google Patents

Download PDF

Info

Publication number
JP2009523777A5
JP2009523777A5 JP2008550839A JP2008550839A JP2009523777A5 JP 2009523777 A5 JP2009523777 A5 JP 2009523777A5 JP 2008550839 A JP2008550839 A JP 2008550839A JP 2008550839 A JP2008550839 A JP 2008550839A JP 2009523777 A5 JP2009523777 A5 JP 2009523777A5
Authority
JP
Japan
Prior art keywords
group
deoxyactagardine
alkyl
compound
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008550839A
Other languages
English (en)
Japanese (ja)
Other versions
JP5219837B2 (ja
JP2009523777A (ja
Filing date
Publication date
Priority claimed from GBGB0600928.6A external-priority patent/GB0600928D0/en
Application filed filed Critical
Publication of JP2009523777A publication Critical patent/JP2009523777A/ja
Publication of JP2009523777A5 publication Critical patent/JP2009523777A5/ja
Application granted granted Critical
Publication of JP5219837B2 publication Critical patent/JP5219837B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008550839A 2006-01-17 2007-01-17 A.ガルバジネンシスおよびa.リグリエに由来するランチビオティック生合成遺伝子クラスター Expired - Fee Related JP5219837B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0600928.6 2006-01-17
GBGB0600928.6A GB0600928D0 (en) 2006-01-17 2006-01-17 Improvements relating to lantibiotics
PCT/GB2007/000138 WO2007083112A2 (en) 2006-01-17 2007-01-17 Lantibiotic biosynthetic gene clusters from a. garbadinensis and a. liguriae

Publications (3)

Publication Number Publication Date
JP2009523777A JP2009523777A (ja) 2009-06-25
JP2009523777A5 true JP2009523777A5 (US07794700-20100914-C00152.png) 2010-03-04
JP5219837B2 JP5219837B2 (ja) 2013-06-26

Family

ID=35998187

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008550839A Expired - Fee Related JP5219837B2 (ja) 2006-01-17 2007-01-17 A.ガルバジネンシスおよびa.リグリエに由来するランチビオティック生合成遺伝子クラスター

Country Status (20)

Country Link
US (3) USRE45003E1 (US07794700-20100914-C00152.png)
EP (2) EP2189472A1 (US07794700-20100914-C00152.png)
JP (1) JP5219837B2 (US07794700-20100914-C00152.png)
KR (1) KR101573536B1 (US07794700-20100914-C00152.png)
CN (1) CN101389641B (US07794700-20100914-C00152.png)
AT (1) ATE534659T1 (US07794700-20100914-C00152.png)
AU (1) AU2007206769B2 (US07794700-20100914-C00152.png)
BR (1) BRPI0706525A2 (US07794700-20100914-C00152.png)
CA (1) CA2637315A1 (US07794700-20100914-C00152.png)
CY (1) CY1112559T1 (US07794700-20100914-C00152.png)
DK (1) DK1979375T3 (US07794700-20100914-C00152.png)
ES (1) ES2378090T3 (US07794700-20100914-C00152.png)
GB (1) GB0600928D0 (US07794700-20100914-C00152.png)
IL (1) IL192446A0 (US07794700-20100914-C00152.png)
MX (1) MX2008009047A (US07794700-20100914-C00152.png)
NZ (1) NZ569486A (US07794700-20100914-C00152.png)
PL (1) PL1979375T3 (US07794700-20100914-C00152.png)
PT (1) PT1979375E (US07794700-20100914-C00152.png)
SI (1) SI1979375T1 (US07794700-20100914-C00152.png)
WO (1) WO2007083112A2 (US07794700-20100914-C00152.png)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
CN102348718B (zh) * 2009-01-14 2015-06-03 诺瓦克塔生物系统有限公司 去氧阿肽加定衍生物
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
EP2393829A1 (en) 2009-02-04 2011-12-14 Novacta Biosystems Limited Actagardine derivatives
CA2789164A1 (en) * 2010-02-02 2011-08-11 Novacta Biosystems Limited Lantibiotic salts
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
CN103052383A (zh) * 2010-07-14 2013-04-17 诺瓦克塔生物系统有限公司 含有b型羊毛硫抗生素的制剂
GB201013507D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013513D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
GB201013508D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013509D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
WO2014085637A1 (en) * 2012-11-30 2014-06-05 Sentinella Pharmaceuticals, Inc. New lantibiotic derivatives and a process for their preparation
CN103483433B (zh) * 2013-09-10 2015-05-27 中国科学院微生物研究所 一种新型高效的羊毛硫细菌素cerecidin及其应用
CN106188253B (zh) * 2016-08-26 2020-08-18 上海交通大学 抗菌肽Lexapeptide及其制备方法和用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB8507528D0 (en) 1985-03-22 1985-05-01 Lepetit Spa Basis monocarboxyamide derivatives
US5304540A (en) 1988-06-22 1994-04-19 Applied Microbiology, Inc. Pharmaceutical bacteriocin compositions and methods for using the same
IN167138B (US07794700-20100914-C00152.png) 1988-08-17 1990-09-01 Hoechst India
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IT1260505B (it) 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
IL107887A (en) 1992-12-08 2003-07-06 Ambi Inc Stabilized lanthionine containing bacteriocin compositions
US5512269A (en) 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
EP0700998B1 (en) 1994-09-12 2003-11-26 Aventis Pharma Deutschland GmbH Recombinant mersacidin and a method for production
DE69629691T2 (de) 1995-06-23 2004-02-26 Ambi, Inc. Verfahren zur kontrolle von antibiotikaresistenten grampositiven bakterien und behandlung von infektionen
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US5985823A (en) 1997-06-09 1999-11-16 Ambi Inc. Method for the treatment of diarrheal disease and for eliminating particular bacterial populations from the colon
US5958873A (en) 1997-06-09 1999-09-28 University Of Cincinnati Oral formulation for treatment of bacteria-induced diseases of the colon
DE19745583A1 (de) * 1997-10-15 1999-04-22 Hoechst Marion Roussel De Gmbh Neues Lantibiotikum verwandt mit Actagardine, Verfahren zur Herstellung und Verwendung derselben
US6569830B1 (en) 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
HU230396B1 (hu) 2000-06-28 2016-04-28 Smithkline Beecham Plc Nedves őrlési eljárás
GB0110432D0 (en) * 2001-04-27 2001-06-20 Plant Bioscience Ltd Lantibiotic production
WO2002103010A1 (en) 2001-06-14 2002-12-27 Plant Bioscience Limited Methods and materials for targeted gene disruption in actinomycete bacteria
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
US7199230B2 (en) 2002-10-10 2007-04-03 Molichem Medicines, Inc. Nucleic acids encoding duramycin
US7351687B2 (en) 2003-07-18 2008-04-01 Vicuron Pharmaceuticals, Inc. Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
ATE356143T1 (de) 2003-07-18 2007-03-15 Vicuron Pharm Inc Antibiotikum 107891, dessen faktoren a1 und a2, pharmazeutisch unbedenkliche salze und zusammensetzungen, und anwendung davon
US20050271650A1 (en) * 2004-02-17 2005-12-08 Cellmatrix, Inc. Method and composition for angiogenesis inhibition
GB0406870D0 (en) 2004-03-26 2004-04-28 Novacta Biosystems Ltd Improvements relating to the production of lantibiotics
JP2009509519A (ja) 2005-09-27 2009-03-12 ノヴァクタ バイオシステムズ リミティッド ランチビオティックメルサシジンの変種およびそれらの使用
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
ES2895666T3 (es) 2006-10-27 2022-02-22 Capsugel Belgium Nv Cápsulas duras de hidroxipropilmetilcelulosa y proceso de fabricación
US20110150917A1 (en) 2007-06-12 2011-06-23 The University Of British Columbia Small Cationic Antimicrobial Peptides
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
KR20110086582A (ko) 2008-11-24 2011-07-28 센티넬라 파마세티컬즈, 인크. 항균활성이 강화된 란티바이오틱 카르복시아미드 유도체
CN102348718B (zh) 2009-01-14 2015-06-03 诺瓦克塔生物系统有限公司 去氧阿肽加定衍生物
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
EP2393829A1 (en) 2009-02-04 2011-12-14 Novacta Biosystems Limited Actagardine derivatives
EP2216937A1 (en) 2009-02-10 2010-08-11 Alcatel Lucent Alarm notification between customer premises equipment and a remote management server

Similar Documents

Publication Publication Date Title
JP2009523777A5 (US07794700-20100914-C00152.png)
US10774065B2 (en) 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
EP3094629B1 (en) 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
EP3724178B1 (en) 1-(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer
EP1490355B1 (en) Indolylmaleimide derivatives
JP6021805B2 (ja) 腫瘍治療剤
JP4542783B2 (ja) スルホンアミド含有複素環化合物及び血管新生抑制剤とを組み合わせてなる抗腫瘍剤
JP2007517807A5 (US07794700-20100914-C00152.png)
JP2007529421A5 (US07794700-20100914-C00152.png)
JP7458336B2 (ja) γcサイトカイン活性の調節
US20060025420A1 (en) Pharmaceutical compositions for the treatment of female sexual disorders
US20080207572A1 (en) Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma
JP2010509356A5 (US07794700-20100914-C00152.png)
KR100759242B1 (ko) 치료학적으로 유용한 인돌릴-3-글리옥실산 유도체
JP2016531922A (ja) 免疫調節剤としての環式ペプチドミメティック化合物
JP2003500404A5 (US07794700-20100914-C00152.png)
JP2011511075A5 (US07794700-20100914-C00152.png)
JP2006524669A5 (US07794700-20100914-C00152.png)
RU2007106933A (ru) Ингибиторы hsp90
RU2002111866A (ru) Производные N-замещенного индол-3-глиоксиламида - противоопухолевое лекарственное средство и средство, подавляющее ангиогенез (варианты), фармацевтическая композиция и противоопухолевое лекарственное средство (варианты)
JP2021501756A5 (US07794700-20100914-C00152.png)
JP2017525717A5 (US07794700-20100914-C00152.png)
JP2005526794A5 (ja) ベンズイミダゾールおよびマイトジェン活性化およびrhoキナーゼ阻害剤としてのその使用
JP2003519137A5 (US07794700-20100914-C00152.png)
RU2011121354A (ru) Синтетические миметики иммунной защиты и их применение